HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities researchers at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Milestone Pharmaceuticals in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.17) for the quarter, down from their prior forecast of ($0.16). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.46 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04.

Milestone Pharmaceuticals Price Performance

NASDAQ:MIST opened at $2.00 on Wednesday. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $2.75. The stock’s 50-day moving average price is $1.97 and its 200-day moving average price is $1.67. The stock has a market capitalization of $106.66 million, a PE ratio of -2.47 and a beta of 1.78.

Institutional Trading of Milestone Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Valeo Financial Advisors LLC raised its stake in shares of Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the period. Atria Investments Inc raised its position in Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the period. PVG Asset Management Corp purchased a new position in Milestone Pharmaceuticals during the third quarter valued at $46,000. Finally, BML Capital Management LLC lifted its holdings in Milestone Pharmaceuticals by 3.0% during the third quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock valued at $1,727,000 after purchasing an additional 33,196 shares in the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.